Evidence map›Paper›PMID 29110506›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2018

Mouse population-based evaluation of urinary protein and miRNA biomarker performance associated with cisplatin renal injury.

Alison H Harrill, Haixia Lin, Julia Tobacyk, John C Seely

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Natural variation suggests candidate genes underlying Caenorhabditis elegans susceptibility to diverse toxicants.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  4. Fifteen years of the Diversity Outbred mouse model: a review.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  5. Natural variation suggests candidate genes underlyingbioRxiv : the preprint server for biology · 2025
    Article
  6. Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Alison H Harrill1 Department of Environmental and Occupational Health, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Haixia Lin1 Department of Environmental and Occupational Health, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Julia Tobacyk2 Department of Pharmacology, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
John C Seely4 Experimental Pathology Laboratories, Inc., Research Triangle Park, NC 27709, USA.
University of Arkansas for Medical Sciences · USExperimental Pathology Laboratories · USNational Institute of Environmental Health Sciences · US

Funding

Biomolecular Screening and Alternative Approaches for the National Toxicology ProgramZIAES103318 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI CASEY, WARREN · 2016 to 2021
$25.0M
The Role o f Tetrahydrobiopterin (BH4) Bioavailability in Radiation-induced Skin InjuryP20GM109005 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN · 2015 to 2024
$21.1M
Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
Systems Pharmacology and Toxicology Training ProgramT32GM106999 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI PRATHER, PAUL L · 2013 to 2022
$1.4M
Arkansas Center for Clinical Translational ResearchKL2RR029883 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI LOWERY, CURTIS L · 2009 to 2011
$588k
Arkansas Center for Clinical Translational ResearchKL2TR000063 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$459k
NCATS NIH HHS KL2 TR000063NCATS NIH HHS UL1 TR000039NCRR NIH HHS KL2 RR029883NIEHS NIH HHS HHSN273200800005CNIGMS NIH HHS P20 GM109005NIGMS NIH HHS T32 GM106999
6 · The paper itself

Abstract

Discovery and qualification of novel biomarkers with improved specificity and sensitivity for detection of xenobiotic-induced injuries is an area of active research across multiple sectors. However, the majority of efforts in this arena have used genetically limited rodent stocks that lack variability in xenobiotic responses inherent to genetically heterogeneous human populations. In this study, genetically diverse Diversity Outbred (DO) mice were used as a surrogate for human clinical populations to investigate performance of urinary kidney biomarkers against classical preclinical kidney injury biomarkers (blood urea nitrogen [BUN] and serum creatinine). In this study, cisplatin was used as a paradigm kidney toxicant, with female adult DO mice exposed to a single injection (5 mg/kg) of cisplatin or vehicle and necropsied 72 h post-exposure and 18 h following overnight urine collection. Interindividual variability in kidney toxicity was observed, with DO mice experiencing either no tubule cell necrosis or minimal-mild necrosis. A panel of urinary protein biomarkers and profiled miRNAs were assessed by receiver-operating characteristic curves as to their ability to distinguish non-responder versus responder animals, as defined by histopathological evidence of renal tubule cell necrosis. A surprising outcome of these studies was that BUN was elevated alongside of urinary miRNA and protein biomarkers in animals with grade 2 proximal tubular cell necrosis; but not elevated with grade 1 necrosis. These studies demonstrate a novel approach for using a rodent population to better assess sensitivity of candidate biomarkers, especially for proposed clinical applications. Impact statement Recent studies have indicated that several urinary proteins and miRNA species may be suitable as biomarkers for acute kidney injury. A major focus on biomarker qualification is demonstrating improved specificity and sensitivity over gold standard tests. In this study, a mouse population model, Diversity Outbred mice, was used to demonstrate that neither the urinary protein markers nor the miRNA species assayed in urine could reliably detect low severity kidney injury better than blood urea nitrogen. This study has implications for use of these biomarkers in the clinic, where interindividual heterogeneity is present within patient populations and for which the underlying tissue pathology may not be known.

Indexed as

Acute Kidney InjuryAnimalsBiomarkersBlood Urea NitrogenCisplatinCreatinineDisease Models, AnimalFemaleHepatitis A Virus Cellular Receptor 1Kidney TubulesMiceMicroRNAsProteinuriaROC CurveBiomarkersCisplatinCreatinineHavcr1 protein, mouseHepatitis A Virus Cellular Receptor 1MicroRNAsBiomarkerscisplatinDiversity Outbredkidneykidney injury molecule-1miRNA

Identifiers

PMID29110506
PMCPMC5813868
OpenAlexW2767933654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.